12:00 AM
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Solorel macimorelin: Phase IIa started

Aeterna Zentaris began a double-blind, placebo-controlled Phase IIa trial to evaluate AEZS-130 in 18-26 patients with cancer cachexia. The trial is being conducted under a cooperative research and development agreement (CRADA) with the Michael E. DeBakey Veterans Affairs Medical Center, which is funding the study....

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >